Trevi Therapeutics (TRVI) Interest Expenses (2018 - 2026)
Trevi Therapeutics' (TRVI) quarterly Interest Expenses came in at $210000.0 in Q1 2026, up 29.63% year-on-year from $162000.0 in Q1 2025, and down 40.17% quarter-over-quarter from $351000.0 in Q4 2025.
Trevi Therapeutics (TRVI) Interest Expenses (2018 - 2026) Analysis & Trends
Trevi Therapeutics' Interest Expenses history runs 9 years deep, the most recent figure standing at $210000.0 for Q1 2026.
- On a quarterly basis, Interest Expenses rose 29.63% year-over-year to $210000.0 in Q1 2026; TTM through Mar 2026 was $210000.0, a 29.63% increase from a year earlier, with the FY2025 full-year figure at $82.7 million, up 608.91% from the prior year.
- Interest Expenses fell to $210000.0 in Q1 2026 per TRVI's latest filing, from $351000.0 in the prior quarter.
- Across five years, Interest Expenses topped out at $1.4 million in Q1 2024 and bottomed at $1000.0 in Q4 2024.
- The 5-year median for Interest Expenses is $274000.0 (2022), against an average of $438705.9.
- Across the five-year window, Interest Expenses sank 99.41% in 2024 and jumped 35000.0% in 2025, its largest moves.
- Year by year, Interest Expenses stood at $274000.0 in 2022, then tumbled by 38.32% to $169000.0 in 2023, then sank by 99.41% to $1000.0 in 2024, then soared by 35000.0% to $351000.0 in 2025, then tumbled by 40.17% to $210000.0 in 2026.
- Per Business Quant, the three latest TRVI Interest Expenses figures stand at $210000.0 (Q1 2026), $351000.0 (Q4 2025), and $937000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -42,141.15 |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 100,000.00 |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 32.89 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 420.30 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 28.30 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 1.17 Bn |
| 10 | Trevi Therapeutics | 2.54 Bn | 2.54 Bn | - | 210,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 210,000.00 |
| Mar 31, 2026 | 210,000.00 |
| Dec 31, 2025 | 351,000.00 |
| Dec 31, 2025 | 351,000.00 |
| Sep 30, 2025 | 937,000.00 |
| Sep 30, 2025 | 937,000.00 |
| Jun 30, 2025 | 1.03 Mn |
| Jun 30, 2025 | 1.03 Mn |
| Mar 31, 2025 | 162,000.00 |
| Mar 31, 2025 | 162,000.00 |
| Dec 31, 2024 | 1,000.00 |
| Dec 31, 2024 | 1,000.00 |
| Sep 30, 2024 | 216,000.00 |
| Sep 30, 2024 | 216,000.00 |
| Jun 30, 2024 | 1.35 Mn |
| Jun 30, 2024 | 1.35 Mn |
| Mar 31, 2024 | 1.42 Mn |
| Mar 31, 2024 | 1.42 Mn |
| Dec 31, 2023 | 169,000.00 |
| Dec 31, 2023 | 169,000.00 |